Un Jung Kang, MD

Kang Un

Founders Professor of Neurology, Professor in Neuroscience Institute at New York University Grossman School of Medicine Un Jung Kang, MD, is director of Translational Research at the Marlene and Paolo Fresco Institute of Parkinson’s and Movement Disorders, and co-director of Parekh Center for Interdisciplinary Neurology at NYU Grossman School of Medicine.

He was previously chief of the Movement Disorders Division at Columbia University, founded by Dr. Stanley Fahn. Dr. Kang received his medical degree from Johns Hopkins University and completed his neurology residency and movement disorders fellowship training at Columbia University.

His clinical expertise is in movement disorders, including Parkinson’s disease. Dr. Kang studies the molecular and cellular mechanisms of brain circuit plasticity underlying both beneficial and detrimental effects of dopaminergic therapy such as dyskinesia using rodent models with cell type-specific modulation and recording correlated with behaviors. Dr. Kang is also interested in understanding the pathogenesis of neurodegeneration in synucleinopathies including PD by studying biomarkers from patients.

He led the Fox Investigation for New Discovery of Biomarkers (BioFIND) and actively participated in NIH/NINDS and Michael J Fox Foundation biomarker programs.


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.